The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)


Chemical Compound Review

LY 127935     disodium 7-[[2-carboxylato-2-(4...

Synonyms: Shionogi 6059S, AGN-PC-00JSUE, SureCN719333, AG-G-43969, M8158_FLUKA, ...
This record was replaced with 3889.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid


High impact information on 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid


Chemical compound and disease context of 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid


Biological context of 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid


Anatomical context of 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

  • To determine the best method of preventing ascending infection in the management of premature rupture of membranes, antibiotics such as latamoxef sodium, cefoperazone sodium, and cefotaxime sodium were infused directly into the amniotic cavity in 64 patients undergoing induction of labor at term [16].
  • When animals treated with repeated doses of 10-15 microgram/kg of LY 127935 were intraperitoneally infected a significantly smaller elimination rate of bacteria was observed in the peritoneal cavity than in animals injected with saline [13].
  • Moxalactam disodium underwent phase II evaluation to determine its efficacy, safety, and tolerance in the treatment of complicated urinary tract infections (UTI) [17].

Associations of 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid with other chemical compounds


Analytical, diagnostic and therapeutic context of 7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid


  1. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis. Landesman, S.H., Corrado, M.L., Cherubin, C.C., Gombert, M., Cleri, D. Am. J. Med. (1980) [Pubmed]
  2. Comparative in vitro activities of third-generation cephalosporins. Fass, R.J. Arch. Intern. Med. (1983) [Pubmed]
  3. Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new). Yu, V.L., Vickers, R.M., Zuravleff, J.J. Antimicrob. Agents Chemother. (1980) [Pubmed]
  4. Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12. Komatsu, Y., Nishikawa, T. Antimicrob. Agents Chemother. (1980) [Pubmed]
  5. LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Trager, G.M., White, G.W., Zimelis, V.M., Panwalker, A.P. Antimicrob. Agents Chemother. (1979) [Pubmed]
  6. Gram-negative bacillary meningitis. New therapy and changing concepts. Landesman, S.H., Cherubin, C.E., Corrado, M.L. Arch. Intern. Med. (1982) [Pubmed]
  7. The concentration of latamoxef achieved in the bile and gallbladder wall of patients with cholecystitis. Vowden, P., Stewart, J., Fowler, B., Ramsden, C.H., Kester, R.C. J. Antimicrob. Chemother. (1986) [Pubmed]
  8. The activity in vitro of ceftazidime (GR 20263) and moxalactam (LY 127935) against Gram-negative bacteria from hospital patients. Pedler, S.J. J. Antimicrob. Chemother. (1981) [Pubmed]
  9. Structural requirements for antibacterial activity and beta-lactamase stability of 7 beta-arylmalonylamino-7 alpha-methoxy-1-oxacephems. Yoshida, T. Philos. Trans. R. Soc. Lond., B, Biol. Sci. (1980) [Pubmed]
  10. Comparative in vitro activity of LY 127935 (6059-S), seven cephalosporins, three aminoglycosides, carbenicillin, and ticarcillin. Watanakunakorn, C., Glotzbecker, C. J. Antibiot. (1979) [Pubmed]
  11. Straightforward synthesis of 7 alpha-methoxy-1-oxacephems from penicillins. Nagata, W. Philos. Trans. R. Soc. Lond., B, Biol. Sci. (1980) [Pubmed]
  12. A high incidence of bleeding is observed in a trial to determine whether addition of metronidazole is needed with latamoxef for prophylaxis in colorectal surgery. Morris, D.L., Fabricius, P.J., Ambrose, N.S., Scammell, B., Burdon, D.W., Keighley, M.R. J. Hosp. Infect. (1984) [Pubmed]
  13. Modulating effect of subinhibitory concentrations of compound LY 127935 on the virulence of Escherichia coli in the mouse. Pusztai-Markos, Z., Pranada, F., Leimbrock, C. Chemotherapy. (1982) [Pubmed]
  14. Improvement of the rectal bioavailability of latamoxef sodium by adjuvants following administration of a suppository. Nakanishi, K., Masukawa, T., Masada, M., Nadai, T. Biol. Pharm. Bull. (1994) [Pubmed]
  15. Evaluation of moxalactam. Reed, M.D., Bertino, J.S., Aronoff, S.C., Speck, W.T., Blumer, J.L. Clinical pharmacy. (1982) [Pubmed]
  16. Transcervical amnioinfusion of antibiotics: a basic study for managing premature rupture of membranes. Ogita, S., Imanaka, M., Matsumoto, M., Oka, T., Sugawa, T. Am. J. Obstet. Gynecol. (1988) [Pubmed]
  17. Clinical experience in the treatment of complicated urinary tract infection with different doses of moxalactam (lamoxactam). Hautmann, R., Pranada, F., Ahlert, G. International journal of clinical pharmacology, therapy, and toxicology. (1983) [Pubmed]
  18. Evaluation of pharmacy and therapeutics committee drug evaluation reports. Majercik, P.L., May, J.R., Longe, R.L., Johnson, M.H. American journal of hospital pharmacy. (1985) [Pubmed]
  19. Moxalactam concentration in human aqueous humor after intravenous administration. Axelrod, J.L., Kochman, R.S. Arch. Ophthalmol. (1982) [Pubmed]
  20. High-performance liquid chromatographic analysis of a new beta-lactam antibiotic, 6059-S (moxalactam). Konaka, R., Kuruma, K., Nishimura, R., Kimura, Y., Yoshida, T. J. Chromatogr. (1981) [Pubmed]
WikiGenes - Universities